Marker Therapeutics (MRKR) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $21.7 million.
- Marker Therapeutics' Liabilities and Shareholders Equity rose 9921.3% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.5 million, marking a year-over-year increase of 4035.75%. This contributed to the annual value of $22.0 million for FY2024, which is 2858.27% up from last year.
- Per Marker Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $21.7 million for Q3 2025, which was up 9921.3% from $14.8 million recorded in Q2 2025.
- Over the past 5 years, Marker Therapeutics' Liabilities and Shareholders Equity peaked at $88.4 million during Q1 2021, and registered a low of $10.9 million during Q3 2024.
- Moreover, its 5-year median value for Liabilities and Shareholders Equity was $22.0 million (2024), whereas its average is $36.3 million.
- As far as peak fluctuations go, Marker Therapeutics' Liabilities and Shareholders Equity surged by 10604.11% in 2021, and later plummeted by 5803.56% in 2023.
- Marker Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $68.1 million in 2021, then plummeted by 49.48% to $34.4 million in 2022, then plummeted by 50.24% to $17.1 million in 2023, then grew by 28.58% to $22.0 million in 2024, then fell by 1.31% to $21.7 million in 2025.
- Its Liabilities and Shareholders Equity was $21.7 million in Q3 2025, compared to $14.8 million in Q2 2025 and $17.0 million in Q1 2025.